Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
Audrey Abella, 16 Oct 2017
The use of angiotensin converting enzyme (ACE) inhibitors may prevent repeat revascularization in patients who underwent percutaneous transluminal angioplasty (PTA) for peripheral artery disease (PAD) compared with angiotensin receptor blockers (ARB), according to a presentation at APCH 2017.

Benzodiazepines confer little to no increase in all-cause mortality risk

Stephen Padilla
14 Jul 2017

Benzodiazepine initiation is associated with either no increase or at most a small increase in the risk of all-cause mortality, results of a recent study based on an intention-to-treat approach suggest. If ever there is a detrimental effect on all-cause mortality, it is likely to be much lower than previously stated and to have uncertain clinical relevance.

“Residual confounding likely explains at least part of the small increase in mortality risk observed in selected analyses,” according to researchers.

A total of 5,061 deaths occurred among high dimensional propensity score-matched benzodiazepine initiators vs 4,691 deaths among noninitiators (9.3 vs 9.4 events per 1,000 person-years; hazard ratio, 1.00; 95 percent CI, 0.96 to 1.04) over a follow-up period of 6 months. [BMJ 2017;358:j2941]

There was a 4- (1 to 8 percent) to 9-percent (2 to 7 percent) increase in the risk of mortality related to the initiation of benzodiazepine treatment for follow-ups of 12 and 48 months and in subgroups of younger patients and those starting short acting agents.

Secondary analyses comparing 1:1 high dimensional propensity score-matched patients initiating benzodiazepines with an active comparator (ie, patients beginning treatment with selective serotonin reuptake inhibitor [SSRI] antidepressants) indicated that benzodiazepine use correlated with a 9-percent (3 to 16 percent) elevated risk.

“We observed small but statistically significant increases (owing to the large size of the cohort) in mortality risk associated with the initiation of benzodiazepines for follow-ups longer than 6 months, in younger patients, in patients initiating short acting drugs, and in the active comparison with selective serotonin reuptake inhibitor antidepressants,” researchers noted.

These findings do not dismiss the possibility of a modest detrimental effect related to benzodiazepines, but this effect is likely to be much lower than previously reported, they added. [BMJ Open 2012;358:e000850; BMJ 2014;358:g1996]

“Moreover, the direction and extent of the attenuation of the point estimates with high dimensional propensity score adjustment in both the comparisons with benzodiazepine noninitiators and SSRI initiators, and the tight confidence intervals driven by the large size of our study, suggest that residual confounding—rather than a true effect of benzodiazepine drugs—could drive the small increase in mortality risk observed in selected analyses,” researchers said.

In this retrospective cohort study, 1:1 high dimensional propensity score-matched cohort of benzodiazepine initiators and randomly selected noninitiators with a medical visit within 14 days of the start of benzodiazepine treatment (n=1,252,988) between July 2004 and December 2013 were included.

In addressing treatment barriers and confounding, patients filled one or more prescriptions for any medication in the 90 days and 91 to 180 days prior to the index date, and the high dimensional propensity score was measured on the bases of more than 300 covariates. The main outcome was all-cause mortality, determined by linkage with the Social Security Administration Death Master File.

“Benzodiazepines confer their effects through their action on γ-amino-butyric acid (GABA) type A receptors in the central nervous system, which are molecular substrates for the regulation of vigilance, anxiety, muscle tension, epileptogenic activity, and memory functions,” according to researchers. [Nature 1999;358:796-800]

The psychotropic action of benzodiazepines explains the study drug’s association with hypnotic-related side effects, including daytime sleepiness, impairment of psychomotor and cognitive functioning, increased risk of motor vehicle collisions, and increased risk of falls and fractures. [CNS Drugs 2004;358:297-328; Am J Public Health 2015;358:e64-9; Arch Intern Med 2004;358:1567-72; Pharmacoepidemiol Drug Saf 2016;358:66-78]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 
Audrey Abella, 16 Oct 2017
The use of angiotensin converting enzyme (ACE) inhibitors may prevent repeat revascularization in patients who underwent percutaneous transluminal angioplasty (PTA) for peripheral artery disease (PAD) compared with angiotensin receptor blockers (ARB), according to a presentation at APCH 2017.